MEDVi, an online hub for GLP-1 drugs, wants you to know that it's "serious" about helping you lose weight. According to its ...

Investment group Atlas Ventures has closed its fourteenth fund, raising $450 million for the next round of investment ... of incretin therapies like Novo Nordisk's Wegovy (semaglutide) and Eli ...

Novo Nordisk CEO Lars Fruergaard Jorgensen is stepping down per mutual agreement with the company. The company said Friday he ...

Novo Nordisk’s new top executive will need to help the company close the gap with Eli Lilly, fend off emerging rivals and ...

Novo Nordisk stock (NVO) jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first quarter and despite a slight cut to its sales forecast for the year.

Meanwhile, current GLP-1 offerings like Ozempic and Wegovy are also subject to the next round of Medicare drug pricing negotiations in the U.S. “Considering the recent market challenges, the share ...

Weight-loss drug maker Novo Nordisk reported an earnings beat, but sales fell short of expectations. Management gave an encouraging outlook for the rest of 2025. Novo Nordisk trades for less than ...

Novo Nordisk announced Friday that Lars Fruergaard Jorgensen is stepping down by “mutual agreement” with the board—corporate speak for “things aren’t going well and someone has to take ...

Novo Nordisk (NYSE: NVO) stock tumbled 3.9% through 10:45 a.m. ET this morning after the manufacturer of GLP-1 weight loss drugs announced its CEO, Lars Fruergaard Jørgensen, will step down from ...

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an oral version of its blockbuster weight loss drug Wegovy. The Danish drugmaker – which has its U.S ...

COPENHAGEN (Reuters) - Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...